These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37102321)

  • 21. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
    Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
    Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
    Kishi T; Ikuta T; Matsuda Y; Sakuma K; Okuya M; Nomura I; Hatano M; Iwata N
    Mol Psychiatry; 2022 Feb; 27(2):1136-1144. PubMed ID: 34642461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
    Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
    BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study.
    Kadakia A; Dembek C; Liu Y; Dieyi C; Williams GR
    J Med Econ; 2021; 24(1):1212-1220. PubMed ID: 34647502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
    Crespo-Facorro B; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Valdizan EM; Pérez-Iglesias R; Amado-Señaris JA; Teresa Garcia-Unzueta M; Labad J; Correll C; Ayesa-Arriola R
    Schizophr Res; 2017 Nov; 189():134-141. PubMed ID: 28223031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents.
    Crump CJ; Abuelazm H; Ibrahim K; Shah S; El-Mallakh RS
    Expert Rev Neurother; 2024 Aug; 24(8):727-733. PubMed ID: 38864423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lumateperone (Caplyta) for schizophrenia.
    Med Lett Drugs Ther; 2020 Jul; 62(1603):113-116. PubMed ID: 32728011
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Likhitsathian S; Suttajit S; Maneeton N; Maneeton B; Oon-Arom A; Suradom C
    Drug Alcohol Depend; 2021 Feb; 219():108467. PubMed ID: 33385693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
    Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
    Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.
    Yee CS; Bahji A; Lolich M; Vázquez GH; Baldessarini RJ
    J Clin Psychopharmacol; 2022 Mar-Apr 01; 42(2):198-208. PubMed ID: 35020712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
    Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
    Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
    Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
    Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.